Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ:GILD)

109.64 -4.90 (-4.28%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 11, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Gilead Sciences

< Previous 1 2
...
28 29 30 31 32 33 34 35 36
...
61 62 Next >
Gilead Sciences to Release First Quarter 2023 Financial Results on Thursday, April 27, 2023
From Gilead Sciences, Inc.
Via Business Wire
Expert Ratings for Gilead Sciences
Via Benzinga
Dividend Income Update March 2023
It’s dividend income update time. One of my favorite times of the month as I get to review my previous month of passive income received from my dividend income portfolio. 
Via Talk Markets
Could Gilead Sciences Stock Help You Become a Millionaire?
The company's dominant HIV therapies and growing oncology pipeline are delivering. 
Via The Motley Fool
P/E Ratio Insights for Gilead Sciences
Via Benzinga
A Look Into Gilead Sciences' Debt
Via Benzinga
6 Reasons to Buy Gilead Sciences Stock
The healthcare stock could be a solid pillar to build your portfolio around. 
Via The Motley Fool
Gilead Sciences' Debt Overview
Via Benzinga
If You Invested $10,000 in Gilead Sciences in 2013, This Is How Much You Would Have Today
Would you have been better off investing in the S&P 500? 
Via The Motley Fool
Cryoport Supports Clinical Trials And Commercial Therapies Across The High-Growth BioTech Industry: Is Its Current Stock Price An Opportunity?
The global biotechnology industry was worth $859 billion in 2022, and it is predicted to reach $1.6 trillion by 2030, growing at a compound annual growth rate (CAGR) of 8.7% over the forecast period.  
Via Benzinga
3 Dividend Stocks Billionaires Seem to Love
It sometimes pays to follow the lead of successful people. 
Via The Motley Fool
Balm of Gilead’s Manuka Honey Skin Healing Cream Named “Best for Healing Skin Conditions” by US Weekly Magazine
Via Get News
Post-Pandemic Potential: Analysts Eye InflaRx COVID-19 Antibody For Market Breakthrough
Via Benzinga
GILD - Chart Of The Week
The daily chart looks pretty strong right now. The stock is trying to break through the resistance line that started around the beginning of December. 
Via Talk Markets
Large Cap Biopharmaceuticals Q1 2023: In This Bullish Run Biotech Lags
It was very difficult to make money in Q1 trading healthcare or biotech ETFs because of the sharp rally in other sectors. Nonetheless, there were two big winners. 
Via Talk Markets
Texas Judge Obstructs Affordable Act Coverage Mandate For Some Cancer Screenings, Prophylaxis
A Texas federal judge reportedly blocked Obamacare's mandate that health insurance plans cover preventive care, including screenings for certain cancers and pre-exposure prophylaxis against HIV (PrEP),... 
Via Benzinga
COVID Remains A Global Threat – NanoViricides Set To Begin Clinical Trials For Pan-Coronavirus Drug To Help Defeat COVID Once And For All
Effective treatments for COVID-19 remain very few and very limited in their capabilities, even after three years. As a result, there are still high rates of hospitalizations and COVID remains many... 
Via Benzinga
ImmuneOnco Banks On Cutting-edge Cancer Drugs To Attract IPO Cash
Key Takeaways: ImmuneOnco’s main product pipeline is a cancer drug targeting a promising protein pathway, the first such drug to enter clinical tests in China, with more intensive trials due in the... 
Via Benzinga
Is It Time to Buy These Ultra-Cheap Dividend Stocks?
These two biopharma stocks aren't exciting growth plays, but they are reliable income vehicles. 
Via The Motley Fool
Why Are Cathie Wood's Ark ETFs Still Trailing Nasdaq Stocks?
From their all-time highs towards the end of 2021, tech stocks have suffered a significant blow from the Federal Reserve's interest rate hike cycle.  
Via Benzinga
Up 463%, This Sizzling Growth Stock Could Have a Lot More Room to Run
Viking Therapeutics stock might in the midst of a historic run. 
Via The Motley Fool
Wall Street's Most Accurate Analysts Say Hold These 3 Health Care Stocks With Over 3% Dividend Yields
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high... 
Via Benzinga
Bunge, Gilead Sciences And A Famous Chocolate Maker On CNBC's 'Final Trades'
On CNBC’s "Halftime Report Final Trades," JP Morgan Private Bank’s Anastasia Amoroso said she is sticking with Invesco QQQ Tru 
Via Benzinga
The 3 Best CRISPR Stocks to Buy Now Before They Skyrocket
Moving forward, CRISPR could revolutionize the way we treat thousands of diseases. The best CRISPR stocks will profit from it. 
Via InvestorPlace
Gilead Sciences Announces $3 Million in Grant Funding to Eight Organizations Addressing HIV Disparities in Rural U.S. Communities
From Gilead Sciences, Inc.
Via Business Wire
A Bull Market Is Coming: Load Up On These 3 Cheap Stocks Today
These stocks are all trading at less than 12 times their future profits. 
Via The Motley Fool
What Is Autologous Cell-Based Therapy, The Treatment Revolutionizing Regenerative Medicine That Could Be Set To Explode Over The Next Few Years?
By Julian Richard, Benzinga 
Via TheNewswire.com
What Is Autologous Cell-Based Therapy, The Treatment Revolutionizing Regenerative Medicine That Could Be Set To Explode Over The Next Few Years?
What Is Autologous Cell-Based Therapy, The Treatment Revolutionizing Regenerative Medicine That Could Be Set To Explode Over The Next Few Years? 
Via News Direct
Gilead's Flagship CAR T-cell Therapy Shows Improved Overall Survival In Pretreated Lymphoma Patients
Via Benzinga
Kite’s Yescarta® CAR T-cell Therapy Demonstrates a Statistically Significant Improvement in Overall Survival for Initial Treatment of Relapsed/Refractory Large B-cell Lymphoma
From Gilead Sciences, Inc.
Via Business Wire
< Previous 1 2
...
28 29 30 31 32 33 34 35 36
...
61 62 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.